SUSAN LAMONICA: Open Payments
NPI 1104568369 · EFFINGHAM, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,171 in 58 payments from 12 companies in 2025. Trend: 2023 $966 · 2024 $834 · 2025 $1,171
Food & beverage: $1,171
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $172 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $166 |
| Teva Pharmaceuticals USA, Inc. | 6 | $152 |
| Neurocrine BioSciences, Inc. | 6 | $142 |
| E.R. Squibb & Sons, L.L.C. | 3 | $140 |
| Alkermes, Inc. | 9 | $139 |
| Janssen Pharmaceuticals, Inc | 6 | $105 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| Axsome Therapeutics, Inc. | 1 | $31 |
| Calliditas Therapeutics US Inc. | 1 | $26 |
Products named: VRAYLAR, CAPLYTA, AUSTEDO XR, INGREZZA, COBENFY, ARISTADA, SPRAVATO, ABILIFY MAINTENA.
Industry payments across IL — which companies pay providers there.
